JBRF is a 501(c)(3) organization that actively promotes and supports scientific research focused on the cause of and treatments for bipolar disorder in children. We are the first and only non-profit foundation dedicated solely to promoting research to identify the source of early-onset bipolar disorder.
The foundation is guided by a remarkable board of directors. Our board is made up of committed parents, treating professionals and world class research investigators who fully recognize the life altering impact that this devastating condition exacts on affected children, their families and communities. We acknowledge the controversy and confusion that surrounds this diagnosis and we firmly believe that the most effective way to clarify the dialogue and find effective treatments is through targeted, science-based research.
JBRF has organized a consortium of collaborating research groups and individual investigators from a number of medical schools and treatment centers including the Albert Einstein College of Medicine, Weill Medical College of Cornell University, New York University School of Medicine, Columbia University College of Physicians and Surgeons, and SUNY-Syracuse, and will continue to establish collaborations with researchers from other centers around the world to further the goals of the foundation.
This scientific and clinical team is organized around a common research aim: to determine the etiology of juvenile-onset bipolar disorder and thereby advance the state of knowledge about this condition so that more effective treatments can be developed.
There are six areas of study towards which research efforts are directed:
Clinical Phenomenology – Diagnosis and Temperamental Features
Neuropsychology – Cognitive deficits/neural circuits
Neuroimaging – Activation paradigms for fMRI studies of fronto-striatal pathways
Neuroendocrinology – Hormonal and neuropeptide markers/circadian rhythms
Chronobiology – Circadian and ultradian rest/activity, thermoregulatory, sleep propensity rhythms
Molecular Genetics – Candidate gene studies
Pharmacological Clinical Studies – Double-blind Placebo Controlled Trial in 6-12 year olds with pediatric bipolar disorder with intranasal ketamine